OMD

Across TCGA pan-cancer cohorts, OMD Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated OMD data layer compared with 19 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher OMD Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OMD expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

PAAD, LIHC, and LUSC are the cancer types where OMD Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.140	0.590	<.001	24	view →
LIHC	OS	Median	All	0.028	0.777	<.001	24	view →
LUSC	DFS	Median	All	0.174	0.645	.048	3	view →
UCEC	DFS	Median	All	1.000	0.635	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

OMD–PAAD (OS)

Open the PAAD breakdown →